Abstract:Background: Multiple myeloma (MM) is a plasma cell cancer for which immunotherapy holds the promise of durable control. To date, cancer vaccines mainly focused on tumor-associated antigens with survivin eliciting protective T-cell responses in both preclinical and clinical studies. Given the success of mRNA vaccines in medicine, we developed Galsomes, lipid nanoparticles containing mRNA and α-galactosyl ceramide to activate both CD8+ T cells and invariant natural killer (iNK) T cells, both potential anti-MM effectors. Materials and Methods: Mouse 5T33MM cells were studied by PCR and flow cytometry (FCM) for expression of survivin and CD1d, respectively. Intravenous (IV) prime-boost Galsome vaccination was performed with a 7-day interval in C57BL6/KalwRij mice that received an IV injection of 5x106 5T33MM cells 3 days earlier. As a control, mice were injected with saline. After 2 weeks, MM burden was studied by serum electrophoresis and FCM, incl. expression of CD1d and PD-L1 on MM cells. Activation of iNKT cells and survivin-specific T cells was studied by measuring IFN-γ secretion in ELISA and dextramer staining. Immunopeptidomics was used to identify new vaccine candidates for which Galsome vaccination is ongoing. Result: The 5T33MM cells showed expression of survivin and CD1d, making it a suitable model for Galsome vaccination. Two weeks following prime-boost vaccination, the serum M-protein was reduced, though not significantly. In contrast, MM cells were significantly reduced in bone marrow and spleen. Expression of CD1d and PD-L1 on MM cells was high but unchanged by Galsome vaccination. Activation of iNKT cells and survivin-specific T cells following prime vaccination was shown. However, following boost vaccination these cell populations reduced significantly compared to control. We repeated prime-boost vaccination in healthy mice, observing a similar outcome. This suggests that the negative effect of the boost Galsome vaccination was not related to immune dysfunctionality due to MM progression. So, we studied the impact of survivin mRNA in the vaccine, as survivin is also expressed in activated T cells, making them a potential target. We observed that iNKT cells and ovalbumin-specific T cells were more reduced when ovalbumin mRNA was paired with survivin mRNA in the Galsomes. To identify other vaccine candidates, we studied peptides eluted from MHC-I/peptide complexes on 5T33MM cells. We selected 4 vaccine candidates including the MM idiotype based on immunogenicity, pathway classification and abundance. mRNA and Galsomes were prepared, and the efficacy of these Galsomes in 5T33MM mice is currently under evaluation. Conclusion: These data show that Galsome vaccination has the potential to reduce MM cell levels. To reach higher efficacy, careful selection of the vaccine antigen is required. Moreover, combination with other immunotherapies might be needed to reach durable disease control. Citation Format: Arne Van der Vreken, Fabien Thery, Sofie Meulewaeter, Karin Vanderkerken, Elke De Bruyne, Kim De Veirman, Lorenzo Franceschini, Rein Verbeke, Francis Impens, Ine Lentacker, Karine Breckpot, Eline Menu. Identification of tumor peptides for therapeutic mRNA vaccination in a mouse multiple myeloma model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4110.

Abstract B052: Recombinant Listeria-Monocytogenes Vaccine Induces Anti-tumor Immune Response in Inflammatory Cell Death Machinery-Deficient Mice

Long-Lasting, Fine-Tuned Anti-Tumor Activity of Recombinant Listeria monocytogenes Vaccine Is Controlled by Pyroptosis and Necroptosis Regulatory and Effector Molecules

Intravenous Delivery of Living Listeria monocytogenes Elicits Gasdmermin-Dependent Tumor Pyroptosis and Motivates Anti-Tumor Immune Response

Immunological evaluation of virulence-deficient Listeria monocytogenes strains in C57BL/6 mice

Abstract 4203: Tumor-targeted delivery of a neoantigen surrogate by non-pathogenic Listeria reduces metastatic ovarian cancer

Abstract 184: M1-like macrophage infiltration, CD8+ T cell activation, and increased cancer cell apoptosis in immunologically cold Lewis lung carcinoma treated with tumor-trophic Salmonella Typhimurium expressing anticancer proteins in immunocompetent C57BL/6 mice

Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer

Abstract B019: Effect of oncolytic vaccinia virus-induced IL-7 and IL-12 expression on tumor immune microenvironment in poorly immunogenic murine cancer

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy

Listeria monocytogenes: a promising vector for tumor immunotherapy

Bacterial Infection with Listeria monocytogenes in Mice and Subsequent Analysis of Antigen-Specific CD8 T Cell Responses

Abstract 4110: Identification of tumor peptides for therapeutic mRNA vaccination in a mouse multiple myeloma model

A Mutant of Listeria monocytogenes Shows Decreased Virulence and Confers Protection Against Listeriosis in Mice

Abstract B059: Signaling Requirements for Enhanced CD8+ T Cell Responses in mRNA Cancer Vaccine Immunotherapy

Aberrant T Helper Cell Response in Tumor-Bearing Mice Limits the Efficacy of Dendritic Cell Vaccine

Abstract 2465: A novel agonist of CD137 as a single agent shows cancer immunoprevention efficacy against various tumor types that is not dependent on the trained immunity

Anti-Tumor Immune Responses in Immune-Reconstituted Mice Injected with A Tumor Vaccine

Abstract 1718: Tumor Eradicated by an Effective in Situ Vaccine Based on a TLR Agonist and an Agonistic Anti-Ox40 Antibody

221. the Utilization of Capsid-Optimized Adeno-Associated Virus (AAV) Vectors for Cancer Immunotherapy

Listeria monocytogenes (Lm)-LLO Immunotherapies Reduce the Immunosuppressive Activity of Myeloid-derived Suppressor Cells and Regulatory T Cells in the Tumor Microenvironment

Abstract A43: Analysis of the effects of therapeutic vaccination with tumor vascular-primed dendritic cells in a mouse model of colon cancer